SIRT1/2 Inhibitor IV, Cambinol is an inhibitor of SIRT1, SIRT2, and SIRT5.
Cambinol has been used:
- as an inhibitor of sirutins (SIRT1 and 2) in hepatocarcinoma cell lines to test its effect on cellular viability and colony formation
- as a SIRT1 and SIRT2 inhibitor to test its effect on frizzled 7 (FZD7) expression in the breast cancer cells MDA-MB-231 and T-47D cells
- as a sirutin inhibitor in L929 cells to test its protective effect against tumor necrosis factor (TNF)-induced cell death
Cambinol is a Sirtuin (Human Silent Information Regulator) Type 1/2 Inhibitor. Sirtuins are structurally and mechanistically unrelated to HDACs Class 1 & 2 deacetylases but share many protein targets. HDAC is a large complex enzyme family involved in epigenetic-control of gene expression. Sirt2 has an IC50 equal to 59 μM.
Cambinol is well tolerated in mice (100 mg/kg) and inhibits growth of Burkitt lymphoma xenografts. No significant weight loss occurs in cambinol-treated animals relative to controls. Inhibitors of NAD-dependent deacetylases may constitute novel anticancer agents[1].
SIRT1: 56 μM (IC50); SIRT2: 59 μM (IC50)
heltweg b, gatbonton t, schuler ad, et al. antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. cancer res. 2006 apr 15;66(8):4368-77.laemmle a, lechleiter a, roh v, et al. inhibition of sirt1 impairs the accumulation and transcriptional activity of hif-1α protein under hypoxic conditions. plos one. 2012;7(3):e33433.